聚乙二醇化重组人粒细胞集落刺激因子免疫原性的研究进展
Research progress on immunogenicity of PEGylated recombinant human granulocyte-colony stimulating factor
王丹阳 1徐婷婷 2邱云良3
作者信息
- 1. 上海工程技术大学化学化工学院,上海 201620;上海益诺思生物技术股份有限公司,上海 201203
- 2. 上海益诺思生物技术股份有限公司,上海 201203;中国医药工业研究总院,上海 201203
- 3. 上海益诺思生物技术股份有限公司,上海 201203
- 折叠
摘要
重组人粒细胞集落刺激因子(recombinant human granulocyte-colony stimulating factor,rhG-CSF)能够有效防治化疗引起的中性粒细胞减少症,其主要通过肾脏代谢,药物半衰期短,需重复注射以维持药效.聚乙二醇(polyethylene glycol,PEG)与rhG-CSF经共价结合制备为PEG-rhG-CSF,可延长药物半衰期,但其在临床应用中可出现由免疫原性介导的不良反应,是需要关注的安全性问题.本文就PEG-rhG-CSF免疫原性引发的不良反应及免疫原性的影响因素、检测方法、产生机制等作一综述,以期为PEG-rhG-CSF的临床安全应用提供参考.
Abstract
Recombinant human granulocyte-colony stimulating factor(rhG-CSF)can effectively prevent and treat febrile neutropenia caused by chemotherapy,which mainly metabolizes through the kidneys and has a short half-life,requiring repeated injections to maintain its effect.PEG-rhG-CSF formed by combining polyethylene glycol(PEG)with rhG-CSF can prolong the half-life of drugs.However,there have been immunogenicity mediated adverse reactions in clinical use of PEG-rhG-CSF,and the safety is still the focus of attention.This paper discusses the adverse reactions induced by PEG-rhG-CSF immunogenicity,as well as the influencing factors,detection methods and production mechanism of immunogenicity with the aim of providing reference for the safe clinical application of PEG-rhG-CSF.
关键词
重组人粒细胞集落刺激因子/聚乙二醇/免疫原性/抗药抗体/不良反应Key words
Recombinant human granulocyte-colony stimulating factor(rhG-CSF)/Polyethylene glycol(PEG)/Immunoge-nicity/Antidrug antibody(ADA)/Adverse reactions引用本文复制引用
基金项目
上海市科委工程技术研究中心专项(17DZ2252900)
出版年
2024
NETL
NSTL
万方数据